Fig. 5
From: Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Anti-proliferative effect of the 6F6 mAb on Difi spheroids. a The Celigo™ imaging cytometer was used to monitor growth and measure the average (AVG) spheroid area over 5 days. Bright-field images of Difi spheroids incubated or not (NT) with the 6F6 mAb or the irrelevant (IRR) mAb (negative control) were acquired every day. b Cell cycle distribution in DiFi spheroids was assessed by quantifying propidium iodide staining with a FC500 flow cytometer after incubation or not (NT) with the 6F6 mAb for 5 days. c Quantification of the number of DAPI-positive cells in Difi spheroids incubated or not (NT) with the 6F6 or the irrelevant (IRR) mAb at day 5. d Zoomed images at day 5 of spheroids incubated or not (NT) with the 6F6 or the irrelevant (IRR) mAb and then stained with EdU (green) and DAPI (blue) for the last 24 h. e After 24 h EdU incorporation, quantification of EdU-positive cells and f measurement of EdU fluorescence intensity at day 5 in spheroids incubated or not (NT) with the 6F6 or the irrelevant (IRR) mAb. * = p < 0.05 (paired t-test)